Induction of apoptosis of human osteoclasts by the transcription factor decoy approach: Relevance for the treatment of rheumatoid arthritis

Minerva Biotecnologica

Volumn 16, Issue 2, 2004, Pages 135-143

  Piva, R ^a   Gambari, R ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Apoptosis; Gene therapy; NF kappa B; Osteoclasis; Transcription factor decoy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BAFILOMYCIN A1; BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; CONCANAMYCIN A; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGONUCLEOTIDE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR;

ANIMAL MODEL; APOPTOSIS; ARTICLE; ARTICULAR CARTILAGE; BONE EROSION; CHONDROPATHY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG TARGETING; HUMAN; IN VITRO STUDY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; SYNOVITIS;

ANIMALIA;

EID: 4844221476     PISSN: 11204826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol 2004;36:372-8.
2. Yamamoto A, Fukuda A, Seto H, Miyazaki T, Kadono Y, Sawada Y et al. Suppression of arthritic bone destruction by adenovirus-mediated dominant-negative Ras gene transfer to synoviocytes and osteoclasts. Arthritis Rheum 2003;48:2682-92.
3. Haugeberg G, Orstavik RE, Kvien TK. Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol 2003;15:469-75.
4. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003;170:2655-62.
5. Xing L, Carlson L, Story B, Tai Z, Keng P, Siebenlist U et al. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. J Bone Miner Res 2003;18:260-9.
6. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002;110:1419-27.
7. Lubberts E, Oppers-Walgreen B, Pettit AR, Van Den Bersselaar L, Joosten LA, Goldring SR et al. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Arthritis Rheum 2002;46:3055-64.
8. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002;61:84-6.
9. Wagner EF, Matsuo K. Signalling in osteoclasts and the role of Fos/AP1 proteins. Ann Rheum Dis 2003;62:83-5.
10. Helfrich MH. Osteoclast diseases. Microsc Res Tech 2003;61:514-32.
11. Mulari M, Vaaraniemi J, Vaananen HK. Intracellular membrane trafficking in bone resorbing osteoclasts. Microsc Res Tech 2003;61:496-503.
12. Troen BR. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 2003;38:605-14.
13. Mackie EJ. Osteoblasts: novel roles in orchestration of skeletal architecture. Int J Biochem Cell Biol 2003;35:1301-5.
14. Haugeberg G, Orstavik RE, Kvien TK. Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol 2003;15:469-75.
15. Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology 2003;42:11-6.
16. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
17. Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003;15:280-7.
18. Zaidi M, Blair HC, Moonga BS, Abe E, Huang CL. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 2003;18:599-609.
19. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002;30:340-6.
20. Jones DH, Kong YY, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 2002;61:32-9.
21. Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 2002;4:281-9.
22. Penolazzi L, Lambertini E, Borgatti M, Piva R, Cozzani M, Giovannini I et al. Decoy oligodeoxynucleotides targeting NF-kappaB transcription factors: induction of apoptosis in human primary osteoclasts. Biochem Pharmacol 2003;66:1189-98.
23. Chen F, Demers LM, Shi X. Upstream signal transduction of NF-kappaB activation. Curr Drug Targets Inflamm Allergy 2002;1:137-49.
24. Heyninck K, Wullaert A, Beyaert R. Nuclear factor-kappa B plays a central role in tumour necrosis factor-mediated liver disease. Biochem Pharmacol 2003;66:1409-15.
25. Tian B, Brasier AR. Identification of a nuclear factor kappa B-dependent gene network. Recent Prog Horm Res 2003;58:95-130.
26. Ito H. IL-6 and Crohn's disease. Curr Drug Targets Inflamm Allergy 2003;2:125-30.
27. Yokota S. Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003;15:581-6.
28. Ishikawa H, Tsuyama N, Kawano MM. Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules. Int J Hematol 2003;78:95-105.
29. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20.
30. Wong PK, Campbell IK, Egan PJ, Ernst M, Wicks IP. The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum 2003;48:1177-89.
31. Mercurio F, Manning AM. Multiple signals converging on NF-kappaB. Curr Opin Cell Biol 1999;11:226-32.
32. Hadjigogos K. The role of free radicals in the pathogenesis of rheumatoid arthritis. Panminerva Med 2003;45:7-13.
33. Barton BE. IL-6: insights into novel biological activities. Clin Immunol Immunopathol 1997;85:16-20.
34. Im GI, Kwon BC, Lee KB. The effect of COX-2 inhibitors on periprosthetic osteolysis. Biomaterials 2004;25:269-75.
35. Collin-Osdoby P, Rothe L, Bekker S, Anderson F, Huang Y, Osdoby P. Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro. J Bone Miner Res 2002;17:1859-71.
36. Armour KJ, van't Hof RJ, Armour KE, Torbergsen AC, Del Soldato P, Ralston SH. Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026). Arthritis Rheum 2001;44:2185-92.
37. Bezerra MM, de Lima V, Alencar VB, Vieira IB, Brito GA, Ribeiro RA et al. Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats. J Periodontol 2000;71:1009-14.
38. Nakagawa N, Yasuda H, Yano K, Mochizuki S, Kobayashi N, Fujimoto H et al. Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. Biochem Biophys Res Commun 1999;265:158-63.
39. Koide M, Murase Y, Yamato K, Noguchi T, Okahashi N, Nishihara T. Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1 alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2. Biochem Biophys Res Commun 1999;259:97-102.
40. Yamasaki K. The role of cyclic AMP, calcium and prostaglandins in the induction of osteoclastic bone resorption associated with experimental tooth movement in rats. J Dent Res 1983;62:877-81.
41. Saito M, Saito S, Ngan PW, Shanfeld J, Davidovitch Z. IL-1β and PGE involved in the response of periodontal cells to mechanical stress. Am J Orthod Dentofacial Orthop 1991;99:226-40.
42. Votta BJ, Bertolini DR. Cytokine suppressive anti-inflammatory compounds inhibit bone resorption in vitro. Bone 1994;15:533-8.
43. Roodman GD. Cell biology of the osteoclast. Exp Hematol 1999;27:1229-41.
44. Okahashi N, Nakamura I, Jimi E, Suda T. Specific inhibitors of vacuolar H+-ATPase trigger apoptotic cell death of osteoclasts. J Bone Miner Res 1997;12:1116-23.
45. Chung HS, Sasaki T, Sato Y, Shibasaki Y. H+-ATPase inhibitor, bafilomycin A1, reduce bone resorption during experimental movement of rat molars. Orthodont Waves 1999;58:183-92.
46. Body JJ. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. Breast 2003;12:37-44.
47. Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003;5:65-74
48. Green JR, Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 2002;25:3-9.
49. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-87.
50. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nature Med 1996;2:1132-6.
51. Lorget F, Kamel S, Mentaverri R, Wattel A, Naassila M, Maamer M et al. High extracellular calcium concentrations directly stimulate osteoclast apoptosis. Biochem Biophys Res Commun 2000; 268:899-903.
52. Shiotani A, Takami M, Itoh K, Shibasaki Y, Sasaki T. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. Anat Rec 2002;268:137-46.
53. Ozaki K, Takeda H, Iwahashi H, Kitano S, Hanazawa S. NF-kB inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells. FEBS Lett 1997;410:297-300.
54. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci US 2000;97:1566-71.
55. Komine N, Kukita A, Kukita T, Ogata Y, Hotokebuchi T, Kohashi O. Tumor necrosis factor-β cooperates with receptor activator of nuclear factor kB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone 2001;28:474-83.
56. Kanzaki H, Chiba M, Shimizu Y, Mitani H. Periodontal ligament cells under mechanical stress induce osteoclastogenesis by receptor activator of nuclear factor kB ligand up-regulation via prostaglandin E2 synthesis. J Bone Miner Res 2002;17:210-20.
57. Cho-Chung YS, Park YG, Nesterova M, Lee YN, Cho YS. CRE-decoy oligonucleotide- inhibition of gene expression and tumor growth. Mol Cell Biochem 2000;212:29-34.
58. Piva R, Gambari R. Transcription factor decoy (TFD) in breast cancer research and treatment. Technol Cancer Res Treat 2002;1:405-16.
59. Cooper JA Jr, Parks JM, Carcelen R, Kahlon SS, Sheffield M, Culbreth R. Attenuation of interleukin-8 production by inhibiting nuclear factor-kappaB translocation using decoy oligonucleotides. Biochem Pharmacol 2000;59:605-13.
60. Kozlov IA, Kubareva EA, Ivanovskaya MG, Shabarova ZA. Design of new reagents on the base of DNA duplexes for irreversible inhibition of transcription factor NF-kappa B. Antisense Nucleic Acid Drug Dev 1997;7:279-89.
61. Vos IH, Govers R, Grone HJ, Kleij L, Schurink M, De Weger RA et al. NFkappaB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J 2000;14:815-22.
62. Nakamura H, Aoki M, Tamai K, Oishi M, Ogihara T, Kaneda Y et al. Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther 2002;9:221-9.
63. Mischiati C, Borgatti M, Bianchi N, Rutigliano C, Tomassetti M, Feriotto G et al. Interaction of the human NF-kappaB p52 transcription factor with DNA-PNA hybrids mimicking the NF-kappaB binding sites of the human immunodeficiency virus type 1 promoter. J Biol Chem 1999;274:33114-22.
64. Romanelli E, Pedone C, Saviano M, Bianchi N, Borgatti M, Mischiati C et al. Molecular interactions between nuclear factor kB (NF-kB) transcription factors and a PNA-DNA chimera mimicking NF-kB binding sites. Eur J Biochem 2001;68:1-11.
65. Pope RM. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2002;2:527-35.
66. Kusunoki N, Yamazaki R, Kitasato H, Beppu M, Aoki H, Kawai S. Triptolide, an active compound identified in a traditional Chinese herb, induces apoptosis of rheumatoid synovial fibroblasts. BMC Pharmacol 2004;4:2.
67. Ogawa Y, Ohtsuki M, Uzuki M, Sawai T, Onozawa Y, Nakayama J et al. Suppression of osteoclastogenesis in rheumatoid arthritis by induction of apoptosis in activated CD4+ T cells. Arthritis Rheum 2003;48:3350-8.
68. Pap T, Cinski A, Baier A, Gay S, Meinecke I. Modulation of pathways regulating both the invasiveness and apoptosis in rheumatoid arthritis synovial fibroblasts. Joint Bone Spine 2003;70:477-9.
69. Perlman H, Nguyen N, Liu H, Eslick J, Esser S, Walsh K et al. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3. Arthritis Rheum 2003;48:3096-101.
70. Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 2003;171:1061-9.
71. Akaike A, Banno Y, Osawa Y, Oshita H, Fushimi K, Kodama H et al. Synergistic induction of apoptosis of rheumatoid arthritis synovial cells by H(2)O(2) and N-acetyl-leucyl-leucyl-norleucinal. J Orthop Sci 2003;8:346-51.
72. Baier A, Meineckel I, Gay S, Pap T. Apoptosis in rheumatoid arthritis. Curr Opin Rheumatol 2003;15:274-9.
73. Highton J, Hessian PA, Kean A, Chin M. Cell death by apoptosis is a feature of the rheumatoid nodule. Ann Rheum Dis 2003;62:77-80.
74. Afeltra A. Treatment of rheumatoid arthritis: new therapeutic approaches with biological agents. Curr Drug Targets Immune Endocr Metabol Disord 2001;1:45-65.
75. Krause A, Scaletta N, Ji JD, Ivashkiv LB. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol 2002;169:6610-6.
76. Van Offel JF, Schuerwegh AJ, Bridts CH, Stevens WJ, De Clerck LS. Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes. Ann Rheum Dis 2002;61:925-8.
77. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci US 2002;99:10025-30.
78. Ottonello L, Frumento G, Arduino N, Bertolotto M, Mancini M, Sottofattori E et al. Delayed neutrophil apoptosis induced by synovial fluid in rheumatoid arthritis: role of cytokines, estrogens, and adenosine. Ann N Y Acad Sci 2002;966:226-31.
79. Borgatti M, Lampronti I, Romanelli A, Pedone C, Saviano M, Bianchi N et al. Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem 2003;278:7500-9.
80. Gambari R. Biological activity and delivery of peptide nucleic acids (PNA)-DNA chimeras for transcription factor decoy (TFD) pharmacotherapy. Curr Med Chem 2004;11:763-71.
81. Borgatti M, Romanelli A, Saviano M, Pedone C, Lampronti I, Breda L et al. Resistance of decoy PNA-DNA chimeras to enzymatic degradation in cellular extracts and serum. Oncol Res 2003:13:279-87.
82. Borgatti M, Breda L, Cortesi R, Nastruzzi C, Romanelli A, Saviano M et al. Cationic liposomes as delivery systems for double-stranded peptide nucleic acid (PNA)-DNA chimeras exhibiting decoy activity against nuclear factor-kB transcription factors. Biochem Pharmacol 2002;64:609-16.
83. Cortesi R, Mischiati C, Borgatti M, Breda L, Romanelli A, Saviano M et al. Formulations for natural and peptide nucleic acids based on cationic polymeric submicron particles. AAPS Pharm Sci 6 January 2004.
84. Gambari R. New trends for the development of novel decoy molecules against nuclear factor kappa-B (NF-kB) transcription factor. Minerva Biotecnol. In press 2004.
85. Brezniak N, Wasserstein A. Orthodontically induced inflammatory root resorption. Part I: The basic science aspects. Angle Orthod 2002;72:175-9
86. Wiebe SH, Hafezi M, Sandhu HS, Sims SM, Dixon SJ. Osteoclast activation in inflammatory periodontal diseases. Oral Dis 1996;2:167-80.